Insider buying last 90 days
No open-market insider purchases were filed for CAI in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Caris Life Sciences moved this week on third-quarter results, with revenue growth of 27% driven by molecular profiling services and approximately 61,500 clinical cases across over 358,000 total oncology tests. The company raised its 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29%, while reporting lower quarterly profit tied to increased spending on its sales force, marketing and new tests. Earnings and revenues topped estimates, compared with $0.08 per share a year ago, and a separate filing disclosed FMR LLC and Abigail P. Johnson's 13.4% beneficial ownership stake as of 30 September 2026.
Shares closed at $25.57, up 1.3%, sitting between the 50-day average of $29.48 and the 200-day average of $21.67. The one-month return stands at -13.9% against a six-month return of 60.4%. The GekkoIndex reads 68.3, placing CAI in the Accumulation zone, up 15.4 over five days. The price sits 16.6% below Gekko Fair Value of $30.67.
The next earnings date falls on 25 February 2027, 107 days out and beyond a typical 20-trading-day hold. No insider, Congress or unusual options activity appears in the current windows. Two billionaire holders are recorded. Analyst coverage shows 6 buy and 3 hold ratings among 9 firms, with a consensus target of $32.46. Typical 20-day price movement runs near 12.5%, worth noting given recent volatility.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Caris Life Sciences scores 3 supportive, 1 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed0 headwinds
Averages disagree
Close $23.04 sits between the 50-day ($29.39) and 200-day ($21.63) averages, or the averages disagree.
See the chart67.9, Accumulation
Reading 67.9 is in the Accumulation zone.
See the GekkoIndex26.5% below
Price is 26.5% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Caris Life Sciences closed at $23.04 on Nov 13, 2026, −7.0% over the past year, inside a 52-week range of $14.19 to $36.50.
Use the left and right arrow keys to read daily values.
Put CAI on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Caris Life Sciences applies artificial intelligence to molecular profiling, giving clients in the United States and abroad detailed analysis of disease at the molecular level. It is known for tools that examine tissue and blood samples to inform cancer-related medical decisions, combining large sets of molecular data with machine learning to guide treatment choices.
Its offerings include MI Profile, which studies tissue samples, and Caris Assure, a blood-based test used in cancer care. Beyond these diagnostic products, the company works with biopharmaceutical firms, supporting their research and development through laboratory services, data analysis, and collaborative research projects.
Caris Life Sciences was founded in 2008 and is headquartered in Irving, Texas. Its shares are listed on the NASDAQ under the ticker CAI.
Caris Life Sciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.9, in the Accumulation zone, up 0.1 points over five sessions.
Up 0.1 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 33 | +1.3% | +5.0% | ||
| Accumulation (current zone) | 122 | −0.4% | +2.4% | ||
| Neutral | 170 | +1.2% | +1.6% | ||
| Distribution | 18 | +0.5% | +7.9% | ||
| Selling | 2 | Too few readings yet | |||
Average CAI share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Caris Life Sciences trades 26.5% below Gekko Fair Value of $31.33, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Caris Life Sciences shares are worth, recalculated every trading day.
$31.33
Gekko Fair Value, Nov 14, 2026
26.5% Undervalued
At the end of Sep 2026 the price was 25.7% above the estimate.
No open-market insider purchases were filed for Caris Life Sciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for CAI in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in CAI were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Caris Life Sciences has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold CAI.
Caris Life Sciences reports on Feb 25, 2027, after the close (102 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 25, 2027
Expected after the close, 102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 4, 2026 | $0.05 est $0.03 | $275.4M est $255.4M | −20.8% |
| Aug 5, 2026 | $0.00 est $0.01 | $263.7M est $238.1M | +24.2% |
| May 7, 2026 | $0.00 est −$0.02 | $216.2M est $209.4M | −15.6% |
| Feb 26, 2026 | $0.28 est $0.10 | $292.9M est $240.4M | +10.0% |
| Nov 5, 2025 | $0.08 est −$0.08 | $216.8M est $280.9M | −21.1% |
| Aug 12, 2025 | −$0.54 est −$0.21 | $181.4M est $137.7M | +13.5% |
| Jun 9, 2025 | −$0.35 est −$0.22 | $120.9M est $138.0M | — |
| Nov 5, 2021 | $2.95 est $0.61 | $100.8M est $90.24M | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Caris Life Sciences is $34.23, +48.6% from the last close, from 11 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 11 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Piper Sandler | $25 | +8.5% |
| Nov 10 | Guggenheim | $36 | +56.3% |
| Nov 6 | Citi | $36 | +56.3% |
| Nov 5 | Goldman Sachs | $35 | +51.9% |
| Nov 5 | Robert W. Baird | $33 | +43.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Caris Life Sciences’s market cap is $6.61B, with a P/E ratio of 14.4 and revenue of $1.05B over the last twelve months.
2 headlines about Caris Life Sciences from the past week, newest first, each linking to the publisher.
Caris Life Sciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Caris Life Sciences’s market cap is $6.61B at the Nov 13, 2026 close of $23.04, with 286.8M shares outstanding. The shares trade on a P/E ratio of 14.4.
The consensus analyst 12-month price target for Caris Life Sciences is $34.23, +48.6% from the last close. Of the 11 firms that rated the stock in the last 90 days, 8 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Caris Life Sciences is undervalued: the Nov 13, 2026 close of $23.04 is 26.5% below Gekko Fair Value of $31.33. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Caris Life Sciences is expected to report on Feb 25, 2027, after the market closes (102 days away). Analysts expect earnings of $0.06 per share on revenue of $290.2M. Caris Life Sciences beat the earnings estimate in 5 of its last 8 reports, moving 17.5% on average across the report.
Caris Life Sciences’s 52-week high is $36.50 and its 52-week low is $14.19; it closed at $23.04 on Nov 13, 2026, −7.0% over the past year. Over the last five years the shares peaked at $42.50 on Aug 22, 2025.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 4 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.